Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Colorcon
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: August 13, 2022

GVOKE PFS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Gvoke Pfs patents expire, and when can generic versions of Gvoke Pfs launch?

Gvoke Pfs is a drug marketed by Xeris and is included in one NDA. There is one patent protecting this drug.

This drug has eighteen patent family members in thirteen countries.

The generic ingredient in GVOKE PFS is glucagon. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glucagon profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gvoke Pfs

A generic version of GVOKE PFS was approved as glucagon by LILLY on September 11th, 1998.

  Try it Free

Summary for GVOKE PFS
International Patents:18
US Patents:1
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for GVOKE PFS
What excipients (inactive ingredients) are in GVOKE PFS?GVOKE PFS excipients list
DailyMed Link:GVOKE PFS at DailyMed
Drug patent expirations by year for GVOKE PFS
Drug Prices for GVOKE PFS

See drug prices for GVOKE PFS

US Patents and Regulatory Information for GVOKE PFS

GVOKE PFS is protected by one US patents and one FDA Regulatory Exclusivity.

Patents protecting GVOKE PFS

Methods for producing stable therapeutic formulations in aprotic polar solvents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEVERE HYPOGLYCEMIA

FDA Regulatory Exclusivity protecting GVOKE PFS

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xeris GVOKE PFS glucagon SOLUTION;SUBCUTANEOUS 212097-001 Sep 10, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Xeris GVOKE PFS glucagon SOLUTION;SUBCUTANEOUS 212097-002 Sep 10, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Xeris GVOKE PFS glucagon SOLUTION;SUBCUTANEOUS 212097-001 Sep 10, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Xeris GVOKE PFS glucagon SOLUTION;SUBCUTANEOUS 212097-002 Sep 10, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for GVOKE PFS

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Tetris Pharma B.V Ogluo glucagon EMEA/H/C/005391
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.,
Authorised no no no 2021-02-11
Eli Lilly Nederland B.V. Baqsimi glucagon EMEA/H/C/003848
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Authorised no no no 2019-12-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for GVOKE PFS

See the table below for patents covering GVOKE PFS around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2016201248 See Plans and Pricing
Eurasian Patent Organization 201890704 СПОСОБЫ ПОЛУЧЕНИЯ СТАБИЛЬНЫХ ТЕРАПЕВТИЧЕСКИХ СОСТАВОВ В АПРОТОННЫХ ПОЛЯРНЫХ РАСТВОРИТЕЛЯХ See Plans and Pricing
Australia 2016326749 Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents See Plans and Pricing
Hong Kong 1250644 在非質子極性溶劑中製造穩定的治療性胰高血糖素之製劑的方法 (METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS) See Plans and Pricing
Israel 258298 שיטות לייצור תכשירי גלוקגון יציבים בסולבנטים פולרים אפרוטים (Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Merck
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.